Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease
- Authors: Guarnotta, V.; Ciresi, A.; Pitrone, M.; Pizzolanti, G.; Giordano, C.
- Publication year: 2018
- Type: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/245532
Abstract
Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications